Mount Sinai's Knowledge Management Center for Illuminating the Druggable Genome

西奈山的可药用基因组照明知识管理中心（KMC-IDG）将 组装，组织和可视化从四个研究中的可药用基因组收集的数据， 家族：蛋白激酶、核受体、离子通道和GPCR。KMC-IDG还将尝试将 这些未充分研究的药物靶点在各种疾病中的潜在应用。为了实现这一目标，我们 将从四个领域收集和提取数据：蛋白质/基因/靶标，药物/干扰物， 疾病/表型/副作用，以及来自个体患者的数据。各种管道和工作流程将 将不同疾病的患者群与研究不足的药物靶点联系起来。的 Ma'ayan和达德利实验室有能力在他们之前的基础上成功地实施这个项目 生产力的记录，源代码和数据的基础已经收集和组织，并强大 现有的用户群，可以直接到新开发的门户网站。此外，两个实验室都有强大的 合作的跟踪记录，包括计算识别和实验验证，至少 一种正在研究中的蛋白激酶作为减轻肾纤维化的潜在重要靶点。一个唯一 该项目的创新研究部分是对文献来源的调查， 存在于分子和细胞生物学研究领域的实验偏差。

The Knowledge Management Center for Illuminating the Druggable Genome (KMC-IDG) at Mount Sinai will assemble, organize and visualize data collected from the under-studied druggable genome from the four families: protein kinases, nuclear receptor, ion channels and GPCRs. The KMC-IDG will also attempt linking such under-studied druggable targets for their potential applications in various diseases. To achieve this we will assemble and abstract data from four domains: proteins/genes/targets, drugs/perturbagens, diseases/phenotypes/side-effects, and data from individual patients. Various pipe-lines and workflow will be established to connect clusters of patients from various diseases to under-studied druggable targets. The Ma'ayan and Dudley Labs are well positioned to carry out successfully this project based on their prior track record of productivity, foundation of source code and data that is already collected and organized, and strong existing user base that can be directed to the newly developed portal. In addition, both labs have a strong track record of collaborations including the computational identification and experimental validation of at least one under-studied protein kinase as a potential important target for attenuating kidney fibrosis. One unique and innovative research component of this project is an investigation into the sources of the literature and experimental biases that exist in the molecular and cellular biology research domains.